Hybrid antibodies in cancer diagnosis and therapy.
Monoclonal Antibodies (Mabs) represent a promising tool for cancer diagnosis and therapy. Administration of MAbs alone or conjugated to cytotoxic agents has been attempted but has significant limitations. Another potentially effective approach is the use of bispecific or bifunctional antibodies where the capacity to recognize the tumor cell and the toxic agent or lymphocyte activation molecule are united in one MAb. The hybrid molecule can be produced by chemical linkage between the two parental antibodies, or alternatively by a biological approach that consists in the fusion of the two selected hybridomas. In the resulting quadroma cell the hybridoma immunoglobulin chains recombine randomly to form the bifunctional MAb. In different in vitro and in vivo models, bifunctional MAbs against tumor and CD3 at nanomolar concentration has been shown to promote tumor cell killing by cytotoxic T cells. Specific localization of chemotherapeutic drugs in xenografted tumors has been demonstrated in mice pretreated with hybrid MAbs. The advantages of the hybrid MAb approach are that it should reduce the MAb biodistribution problem and that it involves no chemical manipulation between the functional agent and the MAb molecules.
Ménard
S
S
Division of Experimental Oncology E, Istituto Nazionale Tumori, Milano, Italy.
Canevari
S
S
Colnaghi
M I
MI
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000276:immunology; D006801:Humans; D007159:Immunologic Tests; D007167:Immunotherapy; D009369:Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014407:Tumor Cells, Cultured / Q000276:immunology
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor